QUESTRAN

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Estonia, Finland, France, Germany, Ireland, Japan, Netherlands, New Zealand, South Africa, UK.

Active ingredients

The drug QUESTRAN contains one active pharmaceutical ingredient (API):

1	Colestyramine UNII 4B33BGI082 - CHOLESTYRAMINE
	Colestyramine resin absorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the faeces. This results in an increased faecal loss of bile acids which leads to an increased oxidation of cholesterol to bile acids and a decrease in serum cholesterol levels and low density lipoprotein serum levels.
	Read more about Colestyramine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QUESTRAN Powder for oral suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AC01	Colestyramine	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AC Bile acid sequestrants
Discover more medicines within C10AC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2967E, 9249T
BR	Câmara de Regulação do Mercado de Medicamentos	505105101136318, 562620060000717
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00869146, 04370366
EE	Ravimiamet	1123513, 1510535, 1605271, 1753961
FI	Lääkealan turvallisuus- ja kehittämiskeskus	160531
FR	Base de données publique des médicaments	65691327
GB	Medicines & Healthcare Products Regulatory Agency	32654
IE	Health Products Regulatory Authority	44329, 55591
JP	医薬品医療機器総合機構	2189009R1032
NL	Z-Index G-Standaard, PRK	62820, 62839
NZ	Medicines and Medical Devices Safety Authority	1208
US	FDA, National Drug Code	49884-936, 49884-937
ZA	Health Products Regulatory Authority	D/7.5/39